JC113 (Paediatrics) - A Jaundiced Child: Neonatal Jaundice Flashcards

1
Q

Define neonatal jaundice

Define level of bilirubin for jaundice

Prevalence of neonatal jaundice

A

Neonatal period = first 28 days of life
Jaundice results from bilirubin accumulation in skin and sclera

neonates: jaundice is visible when it reaches 80-100 μmol/L (4.5-6.0 mg/dL)

Clinical jaundice within the first few days of life:
 >50% of term infants
 80% of preterm infants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Difference between jaundice with yellow color vs jaundice with yellow + green hue

A

 Yellow – unconjugated bilirubin

 Yellow with green hue – conjugated bilirubin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Normal physiology of bilirubin processing

A

heme metabolism:

RBC broken down in reticuloendothelial system:

Heme processed to biliverdin&raquo_space; unconjugated bilirubin&raquo_space; binds to albumin and enters hepatic circulation

Liver: Unconjugated bilirubin processed by UDGPT&raquo_space; conjugated bilirubin

Large intestine: Conjugated bilirubin processed by Intestinal B-glucuronidase&raquo_space; Unconjugated bilirubin for excretion or retenter enterohepatic circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Causes of physiological* neonatal jaundice

A
  1. Upstream:
    - High Hb load in neonates (mean 17-19 g/dL)
    - Short RBC lifespan with faster turnover (half-life 80 days)
  2. Downstream: Immature liver metabolic function:
    - Low ligandin = low uptake of bilirubin into liver cells
    - Low conjugation enzyme activity (UDGPT) = poor conjugation function
  3. Enterohepatic circulation:
    - High amount of bilirubin recycled from gut when feeding is minimal in the first 2-3 days of life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Neonatal jaundice

  • Typical time span
  • Investigations for confirmation
A

Natural history:
 Apparent from day 2-3 of life
 Peaks at day 4-5
 Subsides by day 7-14

Laboratory tests:
 Unconjugated hyperbilirubinemia (commonly >170 umol/L)
 Absent/minimal conjugated fraction
 Normal hepatic ductal and parenchymal enzymes
 Blood smear: no evidence of haemolysis (if yes&raquo_space; watch out for kernicterus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Severe NNJ (unconjugated hyperbilirubinemia)

main causes

A

A. Exaggeration of mechanisms responsible for normal neonatal physiologic jaundice

B. Specific underlying pathological conditions:

  • Hemolysis of various causes***
  • Inadequate feeding (higher enterohepatic circulation)
  • Sepsis

C. Breast milk jaundice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Causes of neonatal hemolysis a/w severe NNJ

A

i. Immune causes, e.g. Rhesus incompatibility (Caucasian), ABO incompatibility
ii. Non-immune, e.g. G6PD deficiency
iii. Extravasation of blood and breakdown e.g. cephalhematoma, intraventricular hemorrhage, birth trauma with extensive bleeding
iv. Polycythemia (high RBC load and breakdown)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Differentiate underlying cause of breastmilk jaundice and breastfeeding jaundice

A

Breastmilk jaundice:
Certain ingredients in breast milk slow down conjugation e.g. nonesterified long chain fatty acids, glucuronidase, B-diol)
Presentation: more delayed

Breastfeeding jaundice
- Inadequate breastfeeding in first few days of life
- Less bilirubin excretion in stool
- Bilirubin deconjugated by intestinal B-glucuronidase and reabsorbed into blood (Higher enterohepatic circulation)
Presentation: First few days oflife

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Breast milk jaundice

  • Time span
  • Effect on baby’s health
  • Ix and Tx
A

 Jaundice may be prolonged (i.e. beyond 14 days of life), even up to 2-3 months old

 = benign condition: baby healthy otherwise, thriving

 Ix: all unconjugated (do fractional bilirubin – direct and indirect)

 Tx: self-limiting, advise mothers to continue breastfeeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Complication of severe NNJ *****

Presentation in early, late and end-stage

A

Encephalopathy/ kernicterus:

  • Unconjugated bilirubin can cross lipid layers and blood brain barriers
  • Cause damage to neural tissue (bilirubin neurotoxicity)
Early: 
 Hypotonia
 Hypertonia
 Opisthotonus (like severe tetanus)
 Poor feeding
 Lethargy
 Fever
 Convulsion

Late:
 Extrapyramidal signs (acute dystonia, akathisia, Parkinsonism, tardive dyskinesia)
 Hearing loss

End:
 Death
 Long-term morbidity: Dystonic cerebral palsy, Upward gaze palsy, Hearing loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Risk factors of severe NNJ/ kernicterus

A
  1. Very high unconjugated bilirubin level in blood for a prolonged period
  2. High “free” bilirubin with insufficient albumin
     Low albumin
     Competitive binding to albumin (e.g. drugs)
  3. Hemolysis
  4. Sepsis (albumin = negative acute phase reactant)
  5. Acidosis
  6. Hypoglycemia
  7. Prematurity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Management of severe NNJ and bilirubin toxicity

A
  1. Regularly screen for neonatal jaundice in first 2 weeks of life
  2. Monitor total bilirubin for severity (“free” bilirubin is not readily measurable)
  3. Intervene before plasma bilirubin reaches “risky” level:
     Term: <20mg/dl (340 mol/L)
     Preterm: lower
    - Phototherapy, Mesoporphyrin, Exchnage transfusion, IvIg
  4. Avoid risk factors for kernicterus: prolong hyperbilirubinemia, low albumin, acidosis, hypoglycemia, sepsis, hemolysis…
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Conjugated hyperbilirubinemia in neonate

  • Cut-off of bilirubin level
  • Associated biochemical derangement
A

Direct bilirubin:
 >2mg/dL (35μmol/L); or
 >15% of total serum bilirubin

Associated with other evidence of hepatobiliary disease:
 Elevated parenchymal/ductal enzymes
 Deranged synthetic functions, e.g. deranged clotting factors, low albumin
 Deranged detoxification functions, e.g. hyperammonemia
 Deranged metabolic function, e.g. hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Causes of conjugated hyperbilirubinemia in Neonatal period

A

Neonatal period:
 Neonatal hepatitis (etiological agents mostly unknown)
 Obstructive: biliary atresia/ choledochal cyst
 Metabolic diseases, e.g. citrin deficiency, galactosemia
 Prolonged parenteral nutrition associated cholestasis
 Syndromal disorders
 Neonatal hemochromatosis (rare)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Causes of Conjugated hyperbilirubinemia beyond neonatal period

A

 Viral hepatitis (A-E)
 Drug-induced hepatotoxicity (e.g. paracetamol)
 Wilson’s disease
 Hemochromatosis, other metabolic diseases
 Others (e.g. choledochal cyst, hereditary hyperbilirubinemia)
 Cystic fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Biliary atresia in neonate

Presentation
Complication
Ix

A

Present during or beyond neonatal period with:
 Prolonged jaundice (obstructive: yellowing of sclera with tinge of green hue)
 Clay-coloured stool
 Tea-coloured urine
 Poor growth
 Enlarged (or shrunken) liver and spleen / abdominal distension

Complication:
progressive obliterative cholangiopathy due to ductal obstruction:
- atresia (closure) of biliary tract
- continuing inflammation of duct epithelium
- hepatitis (hepatic parenchymal damage) and cirrhosis

Ix: conjugated hyperbilirubinemia

17
Q

Biliary atresia in neonate

Management options
Outcomes

A

portoenterostomy (Kasai operation) - Best effect before 12 weeks

  • Jaundice clear
  • Jaundice recur due to liver failure

Paediatric liver transplant - refractory to Kasai operation
- 90% 10-year survival

18
Q

Paediatric liver transplant

  • Indications
  • Source of liver
A

Indication:
- Mostly done for biliary atresia; failed Kasai operation
- Effects of biliary atresia
 Progressive liver failure (no improvement)
 Growth retardation
 Recurrent cholangitis
 Portal hypertension

Source:
LDLT (living donor) or DDLT (deceased donor)

19
Q

Outline history taking questions for neonatal jaundice

A
  1. Compatible with natural course of “physiologic” jaundice? (jaundice within 24h of life is never physiological)
  2. Find pathological causes:
    - Preterm, low birth weight
    - Prenatal complications e.g. gestational DM causing chronic intrauterine hypoxia and polycythaemia
    - Feeding habits and urine/ bowel output (TPN/ low feeding increases enterohepatic circulation)
    - Blood group (ABO incompatibility and Rh)
    - G6PD status
    - Sepsis
    - Age of life
    - Birth trauma (extravasation of blood and breakdown, e.g. IVH, Cephalohematoma)
20
Q

P/E for neonatal jaundice

A

Severity of jaundice:
 Skin, sclera
 Transcutaneous bilirubinometer: measure at forehead and sternum

General exam:
- Hydration
- Pallor (hemolytic anemia)
- Plethora (polycythemia)

Etiology:
- Cephalhematoma/bruises (birth trauma > increased red cell load)
- Size of liver and spleen - Hematosplenomegaly (hemolysis/ obstructive jaundice e.g. biliary atresia)
- Neurological exam - signs of neurotoxicity (kernicterus)

21
Q

First-line investigations for neonatal jaundice

A
  1. Total serum bilirubin
  2. Fractional bilirubin (direct, indirect)
  3. LFT
  4. Blood smear (hemolysis)
22
Q

Define low, medium and high risk NNJ by total serum bilirubin levels

A

Higher risk = more premature + risk factors (e.g. sepsis, hypoglycemia, hemolysis, hyperbilirubinemia, acidosis, birth trauma, low albumin) = lower ‘photo level’ i.e. give PDT at a lower bilirubin level than normal

23
Q

Treatment options for neonatal jaundice

A
Unconjugated hyperbilirubinemia:
A. Phototherapy
B. Exchange transfusion
C. IVIg - for Immune Hemolytic Jaundice 
D. Mesoporphyrins

Obstructive jaundice = surgical treatment by Kasai operation

24
Q

Phototherapy for NNJ

  • Indication
  • MoA
  • S/E
A

Indication: Serum bilirubin above photo level

Mechanism:
Photo- isomerisation of bilirubin to less toxic (hydrophilic) and readily excretable forms (in bile and urine)

Administration:
Wavelength: 460 ul (blue light spectrum)

Side effects Mild:
 Corneal/ retinal damage (use eye shield)
 Dehydration
 Skin rash (transient)
 Loose stool (transient)
25
Q

Exchange transfusion for NNJ

  • Indication
  • MoA
  • S/E
A

Indication:

  • Plasma bilirubin reaches a dangerous level (e.g. >380 umol/l); or
  • Child already shows signs of neurotoxicity

MoA

  • exchange of patient’s blood to rapidly remove plasma bilirubin to safe level
  • Insertion of central line

S/E: high risk, avoid if necessary by regular screening